AbbVie could be heading for its second acquisition in the space of a month, with reports emerging of late-stage negotiations with Gilgamesh Pharmaceuticals, a central nervous system (CNS) drug ...
AbbVie has agreed to pay $65 million on an option deal with start-up Gilgamesh Pharma, lining up rights to neuroplastogen compounds that can improve neuroplasticity - the ability of the brain to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results